Medlive Technology Co vs Veeva Systems Inc Class A: Fair Value & Quality
Both stocks run through our valuation models. Here is how Medlive Technology Co (2192) and Veeva Systems Inc Class A (VEEV) compare, as of Aug 17, 2026.
As of Aug 17, 2026, Fair Value Calculator sees Medlive Technology Co as the less overvalued of the two: Medlive Technology Co trades at HK$7.95 versus a fair value of HK$6.54 (-18%), while Veeva Systems Inc Class A trades at $244 versus $91.49 (-62%).
Medlive Technology Co
2192.HK · HKD · Health Care
-18%
upside to fair value
overvalued
PriceHK$7.95
Fair ValueHK$6.54
Quality75/100
Veeva Systems Inc Class A
VEEV · USD · Health Care
-62%
upside to fair value
overvalued
Price$244
Fair Value$91.49
Quality72/100
Head-to-head numbers
Green value = the better side for that row (for valuation multiples: lower = cheaper).
Medlive Technology CoVeeva Systems Inc Class A
Valuation
13.7×P/E (TTM)33.6×
8.18×P/S (TTM)9.31×
1.08×P/B4.28×
15.4×EV/EBITDA28.7×
1.75×PEG0.85×
3.8%Dividend yield0.0%
HK$0.26Dividend per share—
Profitability
52%Net margin28%
30%Operating margin31%
7%Return on equity14%
2%Return on assets7%
Growth
5%Revenue growth (YoY)16%
26.9%Avg. growth/yr (3Y)14.0%
24.6%Avg. growth/yr (5Y)16.9%
Balance & size
$669MMarket cap$31B
mixedGrowth qualityhealthy
Medlive Technology Co leads: 8 to 5 metric wins.
Dash = not meaningfully computable, for example with negative equity.
Quality in detail
The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.
Medlive Technology Coof which business quality 71 · market factors 32Veeva Systems Inc Class Aof which business quality 72 · market factors 55
ProfitabilityMargins and returns on capital today
40
57
Quality GrowthAre margins and returns improving?
68
65
CashflowEarnings quality: real cash, not paper profit
InvestmentDisciplined investing over empire-building
88
33
Low VolatilityCalm price path (market factor)
71
55
MomentumPrice trend over the last 3–12 months (market factor)
20
63
52W MomentumDistance to the 52-week high (market factor)
8
39
Net IssuanceBuybacks instead of dilution
81
72
What the models say
The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.
Medlive Technology Co
DCF ModelsHK$7.71
Earnings-BasedHK$13.29
Dividend DiscountHK$4.09
MultiplesHK$5.60
Asset-BasedHK$4.41
Growth DCFHK$7.22
Economic ProfitHK$5.06
Growth EarningsHK$16.68
18 of 26 models see the stock below the current price.
Veeva Systems Inc Class A
DCF Models$214
Earnings-Based$142
Dividend Discount$0.41
Multiples$93.60
Asset-Based$29.76
Growth DCF$200
Economic Profit$57.47
Growth Earnings$185
23 of 26 models see the stock below the current price.
Scenario ranges
From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.
Medlive Technology Co
Bear HK$6.21Fair Value HK$6.54Bull HK$6.96
HK$7.95 = current price (white tick)
Veeva Systems Inc Class A
Bear $70.65Fair Value $91.49Bull $138
$244 = current price (white tick)
Compare two other stocks
Tap a field and type again, ticker or company name.
Free, no sign-up
Ranked within their sector
Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.
Medlive Technology Co · Health Care
Quality score75 · Top 25%
Fair value upside-18% · above median
Veeva Systems Inc Class A · Health Care
Quality score72 · Top 25%
Fair value upside-62% · below median
Bottom line
As of Aug 17, 2026, Fair Value Calculator sees Medlive Technology Co as the less overvalued of the two: Medlive Technology Co trades at HK$7.95 versus a fair value of HK$6.54 (-18%), while Veeva Systems Inc Class A trades at $244 versus $91.49 (-62%).
Medlive Technology Co has the higher quality score (75/100).
Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.
A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.
